MULTIPLE SCLEROSIS, RELAPSING-REMITTING

This study aimed to test a new treatment called CABA-201, a CAR T-cell therapy made from a patient's own immune cells, for people with multiple sclerosis (MS). The goal was to see if it was safe and could control the disease by targeting and resetting the immune system. However, …

This study compares the standard fixed-interval dosing of ocrelizumab (every 24 weeks) with a personalized approach where infusions are given only when B cell levels rise above a certain threshold. The goal is to see if the personalized schedule is just as good at preventing rela…

This study looks at how well ofatumumab (Kesimpta®) works for people with relapsing-remitting multiple sclerosis (RRMS) in real-life settings across Italy. About 379 adults already prescribed the drug will be followed for 12 months to measure relapse rates and thinking speed. The…

This phase 3 study tests an oral medication called IMU-838 against a placebo in about 1,100 adults with relapsing multiple sclerosis (MS). The goal is to see if the drug can reduce the number of relapses and new brain lesions over 72 weeks. Participants must be 18-55 years old wi…

This study looks at people with relapsing-remitting multiple sclerosis who switched from the drug MabThera to a similar, lower-cost medicine called Rixathon. Researchers want to see if the switch changes signs of nerve damage, new brain lesions, relapses, or disability. They will…

This trial compares two treatment strategies for people with relapsing-remitting multiple sclerosis: starting with high-efficacy drugs early versus starting with standard first-line therapies and switching if needed. The study involves 900 participants across multiple sites and t…

This study tests a drug called BIIB017 (Plegridy) in teenagers aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). It compares Plegridy to another MS drug, Avonex, to see which is safer and more effective at reducing relapses. The trial involves 152 participants and i…

This pilot study tests whether one-on-one peer support sessions can help people with relapsing-remitting multiple sclerosis stay on their prescribed medications. Sixty adults will be randomly assigned to receive either standard care or three hour-long sessions with a trained peer…

This study tests whether two special diets—a modified Paleolithic elimination diet and a time-restricted ketogenic diet—can improve quality of life, fatigue, and mood in 162 people with relapsing-remitting multiple sclerosis. Participants are assigned to one of the diets or stand…

This study will examine lymph nodes from 5 people with relapsing-remitting multiple sclerosis who are starting ocrelizumab treatment. The goal is to see how effectively the drug removes B cells from lymph nodes, since these cells are known to be important in MS but are not well s…

This study looks at whether combining a special breathing technique (called acute intermittent hypoxia, or AIH) with mild electrical stimulation of leg muscles can boost brain-to-muscle signals in people with relapsing forms of multiple sclerosis. About 40 participants will have …